Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MxiM is a specialized lipoprotein, categorized as a pilotin, that is essential for the assembly of the Type III secretion system (T3SS) in Shigella flexneri (UniProt: P0A204). Its primary biological function is to facilitate the proper localization and insertion of the secretin protein, MxiD, into the bacterial outer membrane (Lario et al., 2005). MxiM binds to the C-terminal S-domain of MxiD within the periplasm and guides it to the outer membrane, likely utilizing the Lol (localization of lipoprotein) pathway (Okuda et al., 2009). In the absence of MxiM, the MxiD secretin fails to form the multimeric pore-like structure required for the T3SS apparatus, leading to the degradation of MxiD and a complete loss of virulence (Schuch & Maurelli, 1997). Because the T3SS is the primary mechanism by which Shigella invades human intestinal epithelial cells to cause shigellosis, MxiM is considered a high-value target for novel antivirulence drugs. Inhibiting MxiM or its interaction with MxiD offers a strategy to disarm the pathogen without directly killing it, potentially reducing the selective pressure for antibiotic resistance (McDonough et al., 2021). This approach is particularly relevant given the increasing prevalence of multi-drug resistant Shigella strains globally. Research into small molecule inhibitors that disrupt the MxiM-MxiD interface is ongoing as a method to treat bacillary dysentery.
Disruption of the MxiM-MxiD interaction to prevent the assembly of the Type III secretion system secretin pore, thereby attenuating bacterial virulence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Secretin pilot protein MxiM (MxiM) (MxiM).